Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, 89081 Ulm, Germany.
Toxins (Basel). 2023 Jun 7;15(6):384. doi: 10.3390/toxins15060384.
infections cause severe symptoms ranging from diarrhea to pseudomembranous colitis due to the secretion of AB-toxins, TcdA and TcdB. Both toxins are taken up into cells through receptor-mediated endocytosis, autoproteolytic processing and translocation of their enzyme domains from acidified endosomes into the cytosol. The enzyme domains glucosylate small GTPases such as Rac1, thereby inhibiting processes such as actin cytoskeleton regulation. Here, we demonstrate that specific pharmacological inhibition of Hsp70 activity protected cells from TcdB intoxication. In particular, the established inhibitor VER-155008 and the antiemetic drug domperidone, which was found to be an Hsp70 inhibitor, reduced the number of cells with TcdB-induced intoxication morphology in HeLa, Vero and intestinal CaCo-2 cells. These drugs also decreased the intracellular glucosylation of Rac1 by TcdB. Domperidone did not inhibit TcdB binding to cells or enzymatic activity but did prevent membrane translocation of TcdB's glucosyltransferase domain into the cytosol. Domperidone also protected cells from intoxication with TcdA as well as CDT toxin produced by hypervirulent strains of . Our results reveal Hsp70 requirement as a new aspect of the cellular uptake mechanism of TcdB and identified Hsp70 as a novel drug target for potential therapeutic strategies required to combat severe infections.
感染会导致严重的症状,从腹泻到伪膜性结肠炎,这是由于 AB 毒素、TcdA 和 TcdB 的分泌。这两种毒素都通过受体介导的内吞作用被细胞摄取,通过自蛋白水解处理和其酶结构域从酸化的内体易位到细胞质。酶结构域使 Rac1 等小 GTPases 糖基化,从而抑制肌动蛋白细胞骨架调节等过程。在这里,我们证明了 HSP70 活性的特异性药理抑制可保护细胞免受 TcdB 中毒。特别是,已建立的抑制剂 VER-155008 和止吐药多潘立酮,被发现是 HSP70 抑制剂,减少了 TcdB 诱导的 HeLa、Vero 和肠道 CaCo-2 细胞中毒形态的细胞数量。这些药物还降低了 TcdB 诱导的 Rac1 细胞内糖基化。多潘立酮不抑制 TcdB 与细胞的结合或酶活性,但可防止 TcdB 的葡糖基转移酶结构域向细胞质的膜易位。多潘立酮还可防止细胞受到 TcdA 和产毒力更强的 株产生的 CDT 毒素的中毒。我们的研究结果揭示了 HSP70 的需求是 TcdB 细胞摄取机制的一个新方面,并将 HSP70 鉴定为一种新的药物靶点,用于对抗严重的 感染的潜在治疗策略。